Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. - Wikidata - wikimedia - TriplyDB

Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms.

Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms.

http://www.wikidata.org/entity/Q34444579

about

Ketamine and other glutamate receptor modulators for depression in adults Atomoxetine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents Factors affecting treatment adherence to atomoxetine in ADHD: a systematic review A critical appraisal of atomoxetine in the management of ADHD Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study.Atomoxetine changes rat's HR response to stress from tachycardia to bradycardia via alterations in autonomic function.Do Hospital and Community SSRI Usage Patterns in Children and Adolescents Match the Evidence?Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial.Major Depression with ADHD: In Children and Adolescents Off-label use of atomoxetine in adults: is it safe?Major depression and treatment response in adolescents with ADHD and substance use disorder.The Internal, External, and Diagnostic Validity of Sluggish Cognitive Tempo: A Meta-Analysis and Critical Review.Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology.Treating common psychiatric disorders associated with attention-deficit/hyperactivity disorder.When attention-deficit/hyperactivity disorder co-occurs with anxiety disorders: effects on treatment.Outside the Black Box: Re-assessing Pediatric Antidepressant Prescription Atomoxetine: a novel treatment for child and adult ADHD A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review.A review of co-morbid depression in pediatric ADHD: etiology, phenomenology, and treatment.A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities.Estimating the size of treatment effects: moving beyond p values Impact of atomoxetine on health-related quality of life and functional status in patients with ADHD.Polypharmacy with antidepressants in children and adolescents.Toward quality care in ADHD: defining the goals of treatment.Combination pharmacotherapy for psychiatric disorders in children and adolescents: prevalence, efficacy, risks and research needs.The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research.The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.Atomoxetine treatment for children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD): a comprehensive meta-analysis of outcomes on parent-rated core symptomatology.Perspectives in psychopharmacology: spotlight on atomoxetine.The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite.Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study.The impact of childhood traumas, depressive and anxiety symptoms on the relationship between borderline personality features and symptoms of adult attention deficit hyperactivity disorder in Turkish university students.Advancing the study of sluggish cognitive tempo via DSM, RDoC, and hierarchical models of psychopathology.Improvement in global psychopathology increases quality of life during treatment of ADHD with atomoxetine or stimulants.Attention-deficit/hyperactivity disorder Molecular mechanism of noradrenaline during the stress-induced major depressive disorder

P2860

Q24186746-6830B6F2-3962-4E65-827B-D84890518E16 Q24200716-6CC1A9B1-E3A4-4FE9-8663-DF3045D72508 Q26746236-CA529662-73FE-43E2-9E6C-6452ED231FED Q26771187-0EAD6ED9-C0E0-4B6B-A206-699FE696AE9F Q27009995-E7B1797D-D363-43FA-A801-67E35DB2E30C Q33694973-DA1A7128-F6DF-4D7D-AC28-55F9C618EA66 Q33751047-F7F0C1FB-23E9-4990-91C6-FE29069EFD4B Q34124607-B7170634-6D78-43AC-B1CF-4AFAC1796C8A Q34163924-41E42B59-86A1-46AF-94BA-646F5F8178B6 Q34343939-7FB6DD72-6766-4B66-B78A-1ED212C683DF Q34618993-831541C9-F46B-4944-98A7-16A6C344DABC Q35633131-4A67390C-4457-4DCF-A37D-B69291E109A8 Q36610708-B1AE31A0-27C4-41E2-ACDC-FAE3DA9D8681 Q36648476-CDBB7699-490C-44EC-8E78-8DEFB4461DE4 Q36765769-A4F198D8-020A-4C74-8EB2-900717E45E64 Q36902027-42E6DC8A-B52B-4FD3-ABBD-47FA973B68C1 Q37112065-E6201160-47EE-4FA3-A2FC-11A6969D26DD Q37166161-D625D21F-0CB6-404E-83D4-9333480249AC Q37171395-5A493B57-F57E-46C5-8E19-1AF0265962EA Q37224562-5AE798DD-CFE5-49F0-A091-CD56FAB3CE18 Q37235736-C891C464-CD05-4C72-90DC-7DA29B75095A Q37638740-AF985933-DE49-4C81-B037-CD5CC00AED47 Q37654952-684E3F0C-49EA-4F0C-A822-E3622C14CCDA Q37763165-2E7FD230-D2E6-43A3-925E-CF14D606AC07 Q38063355-484DCB0C-5D5B-49E2-8E81-4CCE3F951A7E Q38082894-1396CF7F-D9F5-4CF2-890A-A9CE885FA351 Q38113748-4C3D0EA0-AE25-483C-9CA3-18EB2D23CF0A Q38362252-6862E2A9-7146-4A70-9298-979B544DAFB3 Q38862420-A22FF13B-2429-44CE-806F-310B4DC56AF4 Q39097761-A52123A2-063F-4912-AB41-E157DD4ED732 Q41849467-DEB1C064-8BDD-458F-88A1-AD315765B671 Q41870082-93230525-C738-4871-BBE3-7ECDEE2E1A1A Q42612663-0F5407ED-DD7D-4D8B-BC16-9119D3530536 Q47870860-843F64CE-A06F-404B-BDEE-F429252D6482 Q50420088-A9DBB4F7-5090-4C82-87D9-02126473ECFE Q53043914-9EE7E773-47D9-44F1-9B32-D2C0D945D332 Q56095090-FD252E0E-3759-46D7-8858-EBD2F4057C34 Q56619553-5CCA79A6-EA61-4A14-A1F1-EF8AE4EC8BCF

P2860

Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms.

http://www.wikidata.org/entity/Q34444579

description

2005 nî lūn-bûn

@nan

2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

name

Atomoxetine alone or combined ...... epressive or anxiety symptoms.

@ast

Atomoxetine alone or combined ...... epressive or anxiety symptoms.

@en

Atomoxetine alone or combined ...... epressive or anxiety symptoms.

@nl

type

label

Atomoxetine alone or combined ...... epressive or anxiety symptoms.

@ast

Atomoxetine alone or combined ...... epressive or anxiety symptoms.

@en

Atomoxetine alone or combined ...... epressive or anxiety symptoms.

@nl

prefLabel

Atomoxetine alone or combined ...... epressive or anxiety symptoms.

@ast

Atomoxetine alone or combined ...... epressive or anxiety symptoms.

@en

Atomoxetine alone or combined ...... epressive or anxiety symptoms.

@nl

P1433

Q34444579-E6A09A3D-B967-4565-9A1C-51B32ED6C0D9

P1476

Q34444579-B180C659-4843-4197-9EB8-5885CCEF3CD0

P2093

Q34444579-03437917-DDB1-4AB1-B23E-B6B2B9A71E1B

Q34444579-3B37DFD3-3FB6-4653-BB67-D423DB6440DF

Q34444579-3B657C15-18A7-4B7A-93A1-A46FE9650694

Q34444579-5EE16D40-23D0-401D-87E7-BF91DF7A9CB0

Q34444579-63865383-6937-45F5-8E9B-6E4E634397DC

Q34444579-6D17F2A4-386B-4169-AFC2-95E6CCBDFE99

Q34444579-6F1B07C4-6FC5-49BB-A5A2-8B13B8EF5B68

Q34444579-ACF2AAD7-8A86-4A5E-AD1D-88585B35C6CC

Q34444579-D1F2A7E0-F33F-4F8C-9D7B-208F20946155

Q34444579-FF1F6FD9-26EF-47AE-BEF0-F410020FC426

P304

Q34444579-8E347CB1-CD8A-4BE6-9F99-B9549D4A2D46

P31

Q34444579-B7CA6467-F9BC-44EA-8EC4-A321D49C4316

P356

Q34444579-1850896B-F937-4668-902F-33980EEC5EEF

P433

Q34444579-D33B1A94-EC5F-4EDC-AFA4-062BA5E600C4

P478

Q34444579-805355C7-FD7D-4498-98B0-F473EF86A2F9

P50

Q34444579-3B4E4390-F84A-4647-8A98-53BA6C5BB681

P577

Q34444579-4BEE2220-2316-40A3-93BC-AF1E744427BE

P698

Q34444579-969D5916-163E-41A6-B69F-450985785167

P356

01.CHI.0000169012.81536.38

P1433

Journal of the American Academy of Child and Adolescent Psychiatry

P1476

Atomoxetine alone or combined ...... depressive or anxiety symptoms

@en

P2093

Christopher J Kratochvil

http://www.w3.org/2001/XMLSchema#string

David Duesenberg

http://www.w3.org/2001/XMLSchema#string

David Michelson

http://www.w3.org/2001/XMLSchema#string

Elias H Sarkis

http://www.w3.org/2001/XMLSchema#string

Graham J Emslie

http://www.w3.org/2001/XMLSchema#string

Haitao Gao

http://www.w3.org/2001/XMLSchema#string

Humberto Quintana

http://www.w3.org/2001/XMLSchema#string

Joseph Biederman

http://www.w3.org/2001/XMLSchema#string

Karen Dineen Wagner

http://www.w3.org/2001/XMLSchema#string

L Eugene Arnold

http://www.w3.org/2001/XMLSchema#string

P304

915-924

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/01.CHI.0000169012.81536.38

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey Newcorn

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16113620

http://www.w3.org/2001/XMLSchema#string